Tiziana gains as multiple sclerosis candidate improves second patient

designer491/iStock via Getty Images

• Tiziana Life Sciences (NASDAQ:TLSA) added ~14% in the pre-market Wednesday after the clinical-stage biotech announced clinical improvements in the second patient treated with its multiple sclerosis candidate Foralumab.
• The company noted that the results were similar to those of the first patient with secondary progressive multiple sclerosis (SPMS) after 3-months of intranasal Foralumab.
• According to multiple measures such as clinical and PET imaging analyses, the second SPMS patient also showed an improvement following a three-month course of the fully human anti-CD3 monoclonal antibody at a 50 mcg dose.
• The company has submitted the data to the FDA. The regulator has permitted it to enroll eight more SPMS patients to receive the initial dosing level with a provision for dose escalation up to 100 mcg.
• Read more on the results for the first SPMS patient to receive Foralumab.